RxDoctor Payments Data

Etthan Miller

Family · Wytheville, VANPI 1336546209

Payments from drug & device makers

$8,669in general payments, 2019–2025

Across 434 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$920
  • Novo Nordisk$831
  • Pfizer$502
  • Lilly USA, LLC$428
  • Amgen$392
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,669 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$66,088
Medicare patients
200
Services billed
5,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$96,721
OzempicSemaglutide56$86,414
FarxigaDapagliflozin Propanediol50$69,904
TrulicityDulaglutide49$61,132
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$44,032
JanuviaSitagliptin Phosphate28$37,821
XareltoRivaroxaban23$28,582
LinzessLinaclotide14$20,526
RexultiBrexpiprazole11$18,711
Repatha SureclickEvolocumab11$16,169
MounjaroTirzepatide12$13,215
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,325
VascepaIcosapent Ethyl18$9,789
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,367
MyrbetriqMirabegron12$5,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$502$96,72199 claims
Novo NordiskOzempic$831$86,41456 claims
Lilly USA, LLCTrulicity, Mounjaro$428$74,34761 claims
AstraZenecaFarxiga$1,764$69,90450 claims
GSKTrelegy Ellipta, Breo Ellipta$136$48,28762 claims
MerckJanuvia$30$37,82128 claims
Johnson & JohnsonXarelto$13$28,58223 claims
AbbVieLinzess, Synthroid$920$21,60536 claims
Otsuka America Pharmaceutical, Inc.Rexulti$302$18,71111 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$84$12,32514 claims
Astellas Pharma US IncMyrbetriq$92$5,51112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Wytheville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →